ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Pre-clinical Data On Recent Advances With HIV VLP Vaccine Presented At AIDS Vaccine 07 Conference
Novavax, Inc.
(Nasdaq: NVAX) announced today the oral presentation of a paper entitled
"Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent
Neutralizing Antibody Responses" at the AIDS Vaccine 07 conference in
Seattle by Dr. Weimin Liu, University of Alabama School of Medicine at
Birmingham (UAB). Dr. Liu presented results of pre-clinical immunological
studies of improved HIV-1 virus-like particle (VLP) vaccines being
developed by scientists at Novavax and leading vaccine experts at UAB,
Emory University School of Medicine and Duke University School of Medicine
with funding from the National Institutes of Health.
Commenting on the presentation, Dr. Rahul Singhvi, president and CEO of
Novavax said, "The data presented today demonstrate that immunization with
VLPs containing a consensus envelope protein is a promising approach to
achieving the desired broadly neutralizing antibody response against the
HIV-1 virus. These data also substantiate the promise of our recombinant
VLP technology to design vaccines to ultimately generate an immune response
that can prevent complex diseases such as HIV/AIDS."
Virus-like particles (VLPs) represent an attractive HIV-1 vaccine
platform for a safe and effective vaccine against HIV/AIDS. VLPs have the
potential to mimic the three-dimensional structure of a virus without the
risk of replication or infection. Applications of the VLP technology have
been limited in the past due to very low level incorporation of HIV-1
envelope glycoprotein, the principal target for neutralizing antibody
responses, into the HIV-1 virus or recombinant VLPs. Scientists from Emory
University and UAB, working closely with Novavax scientists reported last
week how to genetically modify the HIV-1 envelope to significantly increase
the content of envelope protein that is anchored to particles (Wang, et
al., J Virol Online, Sept 1, 2007).
In addition to increasing the level of envelope protein in VLPs, the
composition of envelope was modified to make it broadly reactive against
several HIV strains. Genetic variation is a hallmark of HIV-1 infection and
a major obstacle to HIV vaccine development. Scientists contributing to the
current study designed centralized (ancestral and consensus) HIV-1 envelope
constructs to help induce cross-reactive immune responses. One of these
consensus HIV-1 envelope genes was used to generate the HIV-1 VLPs reported
in this study.
In today's presentation, Dr. Liu described that in preclinical studies,
VLP vaccination after DNA priming induced HIV-1 neutralizing antibodies to
tier 1 viruses that are easy to neutralize and to a select number of tier 2
viruses that are much harder to neutralize. The tier 2 viruses include
HIV-1 subtype B viruses, which are common in Europe, Australia, and the
Americas, and subtype C viruses, which are predominant in southern Africa,
China, and India. HIV-1 subtype B and C viruses account for more than 50%
of AIDS worldwide. The study also demonstrated that HIV-1 VLPs formulated
without an adjuvant were as potent as an adjuvanted protein subunit vaccine
with respect to eliciting neutralizing antibody responses to both tier 1
and tier 2 viruses.
Dr. Richard Compans, chairman of the department of microbiology and
immunology, Emory University School of Medicine, and senior investigator on
the research team, said, "This vaccine approach differs from most others
now in clinical trials in that VLPs are designed to produce neutralizing
antibodies. Such antibodies have the potential to block the HIV infection
process at its earliest stage."
Dr. Beatrice Hahn, professor of medicine at the University of Alabama
at Birmingham, added "VLPs represent an exciting new vaccine delivery
platform for HIV, the full potential of which has not yet been realized."
Novavax will support its collaborators in completing pre clinical
studies of the consensus envelope HIV-1 VLP candidate vaccine over the next
12 - 18 months and human clinical trials could begin as early as 2009.
Novavax is developing vaccines to prevent influenza, HIV and other
viral diseases leveraging its proprietary VLP vaccine technology. The
company is conducting a Phase I/IIa clinical trial of a pre-pandemic
influenza VLP vaccine.
About Novavax
Novavax Inc. (Nasdaq: NVAX) is a clinical-stage vaccine company
committed to leading the global fight against infectious disease by
creating novel, highly potent vaccines that are safer and more effective
than current preventives options. Using the company's proprietary
virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is
developing vaccines to protect against H5N1 pandemic influenza, seasonal
flu and other viral diseases. Novavax's particulate vaccines closely match
disease-causing viruses while lacking the genetic material to cause
disease, which provides potential for greater immune protection at lower
doses than current vaccines. With an exclusive portable manufacturing
system that allows for rapid mass-production of vaccines, Novavax is
uniquely positioned to meet global public health needs.
Forward-Looking Statements
Statements herein relating to future financial or business performance,
conditions or strategies and other financial and business matters,
including expectations regarding clinical developments, safety, efficacy
and potency of our vaccines, and supply availability are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act. Novavax cautions that these forward-looking statements are subject to
numerous assumptions, risks and uncertainties, which change over time.
Factors that may cause actual results to differ materially from the results
discussed in the forward-looking statements or historical experience
include risks and uncertainties, including the failure by Novavax to secure
and maintain relationships with collaborators; risks relating to the early
stage of Novavax's product candidates under development; uncertainties
relating to commencing clinical trials and their outcome; risks relating to
the supply and commercialization, if any, of Novavax's proposed product
candidates; dependence on the efforts of third parties; dependence on
intellectual property; competition for clinical resources and patient
enrollment from drug candidates in development by other companies with
greater resources and visibility, and risks that we may lack the financial
resources and access to capital to fund our operations. Further information
on the factors and risks that could affect Novavax's business, financial
conditions and results of operations, is contained in Novavax's filings
with the U.S. Securities and Exchange Commission, which are available at
http://www.sec.gov. These forward-looking statements speak only as of the
date of this press release, and Novavax assumes no duty to update
forward-looking statements.
Novavax, Inc.
http://www.novavax.com
Pre-clinice, datele de pe recente progrese cu HIV VLP vaccin vaccin SIDA prezentat la conferinþã 07 - Pre-clinical Data On Recent Advances With HIV VLP Vaccine Presented At AIDS Vaccine 07 Conference - articole medicale engleza - startsanatate